Holen Sie sich die Stockscreener-App
313.15
2.24%
-7.16
Handel nachbörslich:
313.15
Schlusskurs vom Vortag:
$320.31
Offen:
$317.63
24-Stunden-Volumen:
303.46K
Relative Volume:
1.14
Marktkapitalisierung:
$8.77B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-53.53
EPS:
-5.85
Netto-Cashflow:
$223.75M
1W Leistung:
-14.43%
1M Leistung:
-9.59%
6M Leistung:
+6.57%
1J Leistung:
+4.61%
1-Tages-Spanne:
$306.42
$318.38
1-Wochen-Bereich:
$306.42
$371.84
52-Wochen-Spanne:
$262.12
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
15 CUSHING, IRVINE
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BIO | 313.15 | 8.77B | 2.58B | -778.69M | 223.75M | -5.85 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Protein Engineering Market Projected to Reach USD 7.39 Billion by 2032 with a CAGR of 14.72% - GlobeNewswire Inc.
Mawer Investment Management Ltd. Purchases 84,237 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Genomic Biomarker Market 2024 Opportunity, Challenge, - openPR
Laboratory Mixer Market Strong Industry Growth, Business - openPR
Research Antibodies Market Report Outlines Revenue Share, SWOT - openPR
Genomic Biomarker Market Dynamics and Forecast Comprehensive - openPR
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Lowered by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Clinical Diagnostics Market to Reach $ 110.0 Billion by 2031 | - openPR
Multiplexed Diagnostics Market Share, Trends, Top Players, - openPR
Apoptosis Assays Market Analysis By Top KeyplayersMerck, - openPR
High-throughput Screening Technology Market Size and Regional An - News Channel Nebraska
Principal Financial Group Inc. Increases Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges - BioProcess Insider
Short Interest in Bio-Rad Laboratories, Inc. (NYSE:BIO) Declines By 20.8% - MarketBeat
Chromatography Systems Market Industry Detailed Exploration, - openPR
VAN ECK ASSOCIATES CORP's Strategic Acquisition in Bio-Rad Labor - GuruFocus.com
Chiral Chromatography Columns Market Overall Study Report - openPR
Dental Services Market Overall Study Report 2024-2032 | Agilent - openPR
Genomics Market Overall Study Report 2024-2032 | Agilent - openPR
SEC Form SC 13G filed by Bio-Rad Laboratories Inc. - Quantisnow
Entropy Technologies LP Acquires Shares of 4,200 Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
4,200 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Entropy Technologies LP - MarketBeat
Bio-Rad Demonstrates Leadership Position in the Oncology Market at Association for Molecular Pathology 2024 - Technology Networks
Protein A Resin Market Growth, Size, Trends, Shares, By Top - openPR
Brokerages Set Bio-Rad Laboratories, Inc. (NYSE:BIO) Target Price at $391.80 - MarketBeat
Lung Cancer Diagnostics Market Anticipated for Positive Growth - openPR
Biochips Market Is Booming Worldwide 2024-2031 | Illumina, - openPR
Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination - Morningstar
ICICI Prudential Asset Management Co Ltd Raises Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity? - Insider Monkey
PCR Systems Market Growth, Industry Development and Forecast - openPR
Thalassemia Testing Market Ready to Rise Sharply On Superior - openPR
Bio-Rad demonstrates leadership position in the oncology market at Association for Molecular Pathology 2024 - Cambridge Network
Biosensors Market Is Booming Worldwide 2024-2031 | Bio-Rad - openPR
Biomarker Testing Market: Global Size, Share, Growth Trends, - openPR
Neuroscience Antibodies And Assays Market Forecasted for Major - openPR
Amalgamated Bank Has $3.02 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Hemoglobinopathies Market Size, Growth Opportunities 2031 - openPR
Bio-Rad Laboratories (NYSE:BIO.B) Reaches New 52-Week HighHere's What Happened - MarketBeat
Rovin Capital UT ADV Invests $669,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Monoclonal Antibody Diagnostic Reagents Market Is Booming - openPR
Transfer Membrane Market Size, Insights 2031 by Key Vendors- - openPR
Kornitzer Capital Management Inc. KS Acquires 3,564 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
StarBright Yellow 561: A reliable alternative to PE-tandem dyes - News-Medical.Net
Custom Antibody Market Growth, Drivers, and Opportunities – Exclusive Report by MarketsandMarkets™ - WICZ
[Latest] Global Cancer Cell Analysis Market Size/Share Worth USD 23.31 Billion by 2033 at a 8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Electroporation Instruments And Consumables Market: Global - openPR
Bio-Rad's SWOT analysis: stock outlook amid operational gains, sector headwinds - Investing.com
Harbor Capital Advisors Inc. Raises Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Vanguard Group Inc's Strategic Reduction in Bio-Rad Laboratories Inc Shares - GuruFocus.com
Interpreting Bio-Rad (BIO) International Revenue Trends - Yahoo Finance
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):